Abpro
United States
21 articles about Abpro
-
Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II
1/22/2024
Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination.
-
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II
9/21/2023
Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced a term sheet to enter into a definitive business combination, which was entered into on September 18, 2023.
-
Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.
-
Researchers at Case Western University looked at the real-world experiences of 13,644 patients who were treated with Paxlovid or Lagevrio (molnupiravir) during the first half of 2022.
-
The COVID-19 pandemic will end one day and, when it does, some biopharma companies will need to revert to a more normal way of working with others.
-
Abpro Announces Presentation and Data at the 2021 Annual Association for Research in Vision and Ophthalmology of ABP201 for the Treatment of Wet Age-related Macular Degeneration
5/4/2021
Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, announced results from its study of ABP201, a novel bispecific antibody co-targeting VEGF and ANG2, for treatment of wet age-related macular degeneration and diabetic macular edema.
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
It’s been a busy day so far for biopharma news and updates. Read on for more.
-
BioSpace spoke with a few companies that have some ingenious ideas at different stages of preclinical and clinical development.
-
Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19
11/16/2020
▪ Data from the monkey challenge study published in Nature Communications showed a single dose of neutralizing antibody ABP 300 blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting ▪ Safety demonstrated in non-human primates ▪ ABP 300 showed the potential to neutralize eight SARS-CoV-2 strains with reported high-frequency mutations
-
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets
3/3/2020
Abpro to receive up to $1.1 billion, including a $30 million upfront equity investment, clinical funding, milestones, and royalties
-
Abpro, based in Woburn, Mass., inked a deal worth up to $4 billion with China-based Nanjing Chia Tai Tianqing Pharmaceutical Company, known as NJCTTQ, a global pharmaceutical company.
-
Abpro And Njcttq Enter Into Partnership For Development Of Multiple Novel Bispecific Antibodies
2/28/2019
Abpro eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties
-
A 2013 study that analyzes IPO withdrawals between 1999 and 2004 found that about 13 percent returned later for a successful IPO, 36 percent turned again to raising capital privately, and 42 percent either merged or were acquired by other companies—another common strategy for biotechs. And about ...
-
Movers and Shakers Oct. 1
10/1/2018
Here's a look at who shook things up in the world of pharma and biotech this week. -
Abpro Expands Senior Leadership Team And Announces Appointment Of Gavin MacBeath, Ph.D. As Chief Scientific Officer
3/21/2017
-
Abpro Expands Senior Leadership Team And Announces Adam Mostafa As Chief Financial Officer
2/1/2017
-
MedImmune And Abpro Enter Into A Collaborative Agreement For A Novel Bispecific Antibody
11/29/2016
-
Abpro Announces Agreements With Two Boston Hospitals To Co-Develop Therapeutics For Inflammation, Autoimmunity, Fibrosis And Oncology
5/19/2016
-
Bay State's Abpro Will Hire Using Funding from Chinese Biotech
4/7/2016